Merck Picks Up Hanmi’s Dual Agonist Efinopegdutide, But For NASH
Repurposed Promise In Competitive Indication
Hanmi licenses out GLP-1/glucagon receptor dual agonist for NASH to Merck, in a deal worth up to $870m, marking a positive turn for the Korean firm's pipeline after Janssen returned rights last year.
